AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$10.47 -0.28%

-$0.02 today

Market cap
$3.42B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.48M

Average 6.37M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$131.29M

FY 2025 · Annual

Investing Cash Flow

$87.75M

FY 2025 · Annual

-27.7% YoY

Financing Cash Flow

$14.08M

FY 2025 · Annual

+10.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
Deferred Income Tax(2.02M)(2.11M)1.96M00
Stock-Based Compensation30.65M49.48M64.18M67.58M55.79M
Change in Working Capital41.67M29.83M13.23M(25.84M)(70.69M)
Accounts Receivables22.48M(22.72M)(45.93M)(75.12M)(55.62M)
Inventory0018.25M00
Accounts Payables1.4M1.07M(15.1M)10.64M3.46M
Other Working Capital17.79M51.47M56.01M38.64M(18.53M)
Other Non-Cash Items3.57M8.55M(7.74M)(84.44M)1.2M
Operating Cash Flow244.58M277.36M(43.88M)(108.56M)(131.3M)
Capital Expenditures(58.45M)(72.66M)(77.51M)(78.4M)(42.77M)
Acquisitions (Net)(11.46M)(25.68M)(13.69M)(19.63M)(7.14M)
Purchases of Investments(322.57M)(781.35M)(1.07B)(765.09M)(453.14M)
Sales of Investments27.61M510.63M910.94M948.81M506.07M
Other Investing Activities32.62M16.43M25.31M35.71M84.72M
Investing Cash Flow(332.25M)(352.63M)(221.11M)121.41M87.75M
Debt Repayment(951K)2.76M11.59M13.5M0
Common Stock Issued4.62M0000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(7.55M)(4.38M)(1.23M)(729K)14.08M
Financing Cash Flow(3.89M)(1.63M)10.36M12.77M14.08M
Effect of Forex Changes(1.43M)(9.6M)589K(2.62M)1.1M
Net Change in Cash(92.97M)(86.49M)(254.04M)23.01M(28.37M)
Free Cash Flow186.13M204.7M(121.38M)(186.95M)(174.07M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$146.4M
+ D&A$28.8M
+ Stock-Based Comp$55.8M
+ Deferred Tax$0
- Working Capital-$70.7M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$131.3M
- Capex-$42.8M
= Free Cash Flow-$174.1M

Analysis

FY2025 free cash flow is -$174.1M. FCF conversion is 118.9% of net income. Operating cash flow was -$131.3M, with capex of -$42.8M. The largest bridge item is Working Capital at -$70.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
8-KCurrent reportNov 9, 2026

Does ABCL generate free cash flow?

AbCellera Biologics Inc. (ABCL) generated -$174.07M of free cash flow in fiscal 2025.

How much operating cash flow does ABCL produce?

Operating cash flow was -$131.29M, before capital expenditures of $42.77M.